display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced OC (mOC) - 1st line (L1)metastatic/advanced OC (mOC) - 2nd line (L2)metastatic/advanced OC (mOC) - maintenance (M)
metastatic/advanced OC (mOC) - 1st line (L1)mOC - L1 - all populationmOC - L1 - PDL1 positivemetastatic/advanced OC (mOC) - 2nd line (L2)metastatic/advanced OC (mOC) - maintenance (M)
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel AGO-OVAR 2.29/ENGOT-ov34
atezolizumab plus SoC IMagyn-050 ... IMagyn-050 ...
avelumab based treatment
avelumab alone JAVELIN ovarian 200 ...
avelumab plus pegylated liposomal doxorubicin JAVELIN ovarian 200 ...
avelumab plus SoC JAVELIN Ovarian 100
nivolumab based treatment ATHENA-COMBO ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons